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Abstract
There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of
neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigation of
neurodegenerative disorders has increased substantially over the past decades and continues to provide further
benefits both to the diagnosis and understanding of these diseases. This review forms part of a series of articles
which stem from the University College London/University of Gothenburg course “Biomarkers in neurodegenerative
diseases”. In this review, we focus on neuroimaging, specifically positron emission tomography (PET) and magnetic
resonance imaging (MRI), giving an overview of the current established practices clinically and in research as well as
new techniques being developed. We will also discuss the use of machine learning (ML) techniques within these
fields to provide additional insights to early diagnosis and multimodal analysis.
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Introduction
Neurodegenerative diseases, including Alzheimer’s dis-
ease (AD), are now recognised to start years before
symptoms appear [1]. Studies of the genetically caused
familial AD have proposed a sequence of pathologic
events, starting with build-up and accumulation of
amyloid-β (Aβ), that can now be measured in the brain
(using positron emission tomography (PET) imaging)
and in cerebrospinal fluid (via lumbar puncture) and
ending with cognitive deficits and dementia [2]. These
events appear to start demonstrating abnormalities in a
distinct order, but also overlap temporally.
Specifically considering AD, the National Institute on
Ageing and Alzheimer’s Association (NIA-AA) has de-
veloped the research framework for the diagnosis of AD
[3]. This categorises diagnoses into the AT(N) scale, re-
ferring to Aβ, tau and neurodegeneration. These three
pathologies can all be (spatially and temporally) identi-
fied in vivo with current imaging biomarkers. Further
biomarkers that could be added to contribute to the
ATN categories (as discussed in detail in [3]) could
come from the imaging modalities discussed in this re-
view. Further refinement of diagnostic cut-offs for each
of these imaging-derived biomarkers will then also pro-
vide increases in the sensitivity and specificity for the re-
spective modality.
Neuroimaging has become a standard tool in the clin-
ical work up of individuals suspected of having a neuro-
degenerative disease. The use of various magnetic
resonance imaging (MRI) techniques and the develop-
ment of novel PET ligands have led to the ability to
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understand these diseases in vivo like never before. Ac-
cess to these tools has provided access to a plethora of
objective measures which can indicate both the presence
and progression of these diseases. This is useful for pa-
tients in a clinical setting but can also be used for the
targeted recruitment to clinical treatment trials and
tracking of any treatments that are undergoing clinical
trial both in terms of efficacy of treatment but also for
safety monitoring. Neurodegenerative disorders are in-
creasingly requiring the input of multiple disciplines for
both the diagnosis and understanding of these diseases,
and imaging biomarkers have a role to play in the wider
collaborative approach to understanding these diseases
as well.
There have been considerable advances in the portfo-
lio of PET ligands available for use in identifying bio-
markers associated with neurodegeneration, some of
which have progressed to use in the clinic and others
present promising new avenues for understanding these
neurodegenerative diseases. MRI techniques are also be-
ing used to help with both the diagnosis and the devel-
opment of our understanding, with structural MRI still
being the most widely available imaging tool for neuro-
degeneration. This review article will give a brief over-
view of the established and upcoming practices both
within the PET and MRI fields in relation to neurode-
generation as well as how machine learning can be an
aid to these modalities.
Positron Emission Tomography
[18F]FDG PET
[18F]-2-Fluoro-2-deoxy-D-glucose (FDG) was first intro-
duced as a PET tracer for neuroimaging in 1979 [4] and
has since been established as a routine research and clin-
ical biomarker for diagnosing dementia [5]. Glucose is
the brain’s main source of energy. It circulates in the
blood and crosses the blood-brain barrier. When energy
is needed, glucose is phosphorylated as the first step of
energy being made available. FDG is an artificial
analogue of glucose, which mimics glucose’s action until
it is phosphorylated. Phosphorylated FDG gets trapped
in tissue and is not metabolised further. The rate of
FDG trapping is proportional to glucose metabolism.
Rocher et al. showed that regional glucose consumption
is related to synaptic activity [6], and decreased regional
FDG trapping (hypometabolism) is interpreted as a sign
of synaptic and neuronal damage.
Protocols for acquiring FDG images can vary between
sites. After intravenous injection of FDG into a fasting
subject (fasted for ~ 4 h), and waiting a minimum of 30
min to allow FDG to circulate, PET data is acquired,
typically for 10–30min. Absolute glucose metabolism
can be calculated by using an arterial input function
derived from arterial blood, but more commonly the
standardised uptake value (SUV) is calculated using body
mass (kg) and injected dose of FDG (MBq). Regional
SUV ratios (SUVRs) can be generated using a standard
reference region, normally a region unaffected by the
disease process, e.g. the grey matter of the cerebellum in
AD [7].
Clinical application of FDG PET varies between coun-
tries, but regional neocortical hypometabolism is ac-
cepted to be useful to help differentiate dementias even
though regional patterns can overlap [8–10]. In AD,
hypometabolism can appear before visible atrophy [11]
and a symmetrical hypometabolism in the temporoparie-
tal, posterior cingulate and medial temporal cortices is
usually seen. Reported sensitivity and specificity for AD
diagnosis vary from study to study, but in 2015, Smaila-
gic et al. [12] found the sensitivity for conversion from
mild cognitive impairment (MCI) to AD was 76% at 82%
specificity. In frontotemporal dementia, hypometabolic
regions include the frontal and anterior temporal lobes,
cingulate gyri, uncus, insula, basal ganglia and medial
thalamus. The hypometabolism is often asymmetric [13]
with sensitivity of 88% and specificity of 91%. Occipital
hypometabolism occurs in both posterior cortical atro-
phy (an atypical form of AD) and dementia with Lewy
bodies (DLB) [14]: dopamine transporter imaging could
be used to differentiate these dementia types since dopa-
mine transport is decreased in DLB.
While useful, FDG PET has limitations. Decreased up-
take can be caused by a diminished cerebrovascular cir-
culation or by metabolic disorders such as diabetes
rather than decreased synaptic activity [15]. As the scan
involves radiation exposure, it is not recommended to
be repeated more frequently than annually. The PET
process itself (isotope production, radiochemistry, scan)
is expensive compared to MRI, and [18F] has a short
half-life of just under 2 h (110 min), which adds time
pressure to scans. In summary, FDG PET is a useful
biomarker for investigating neuronal injury in dementia.
Amyloid-β PET
The involvement of Aβ in the pathological expression of
AD has been known for over 25 years [16]. This involves
the aggregation of fibrillar Aβ causing the creation of so-
called Aβ plaques in the brain [17]. The current
hypothesis is that plaque accumulation induces multiple
downstream alterations that lead to neurodegeneration
and cognitive decline. Our understanding of these down-
stream alterations has changed over the years and now
includes not only inflammation but synaptic alterations,
functional changes and alterations in tau [18, 19].
Historically, the only way to definitively classify a person
as having AD was through post mortem examination of
their brain tissue for Aβ plaques and neurofibrillary
tangles (NFTs) predominantly consisting of
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hyperphosphorylated tau protein. With the advent of Aβ
PET tracers, it is now possible to have an in vivo, quanti-
fiable measure of a key biomarker of AD, thereby allow-
ing a possible diagnosis much earlier [20]. Aβ in the
brain displays a pattern of deposition that begins in
medial frontal and basal temporal areas, progressing to
include the neocortex, primary sensory-motor areas and
finally the MTL and striatum [21–23].
The first Aβ-specific PET tracer introduced to pro-
vide accurate imaging data of Aβ pathology is Pitts-
burgh compound B (PiB) labelled with C-11 [24, 25].
The compound is derived from thioflavin-T and is
known to have a high affinity to the Aβ plaques. This
has resulted in its widespread use both as a diagnos-
tic tool and as a reference for other Aβ PET tracers
[25]. While [11C]PiB is useful in research settings, its
widespread utility is limited by the short half-life of
C-11 necessitating a local cyclotron and radiochemis-
try. Therefore, the development of an F-18 (110-min
half-life)-based Aβ tracer was required for routine
clinical use as those can be delivered from an off-site
cyclotron. There are currently three F-18-labelled Aβ
PET tracers approved by the FDA and EMA for
clinical use. These are [18F]flutemetamol, [18F]florbe-
tapir and [18F]florbetaben. These tracers have shown
to behave similarly to PiB in head-to-head studies
[26–28], and some have been verified histologically
[29]. Another Aβ-specific tracer, [18F]NAV4694, is
thought to overcome some of the reported shortcom-
ings of the previous-generation tracers, mainly “off-
target” binding [30]. The range of tracers being used,
all with differing uptake characteristics and varying
pharmacokinetics, means that care must be taken
when performing analyses. Each of these tracers will
require their own analysis pipeline with possible dif-
ferences in reference regions [31, 32]. Cut points for
Aβ positivity will also vary between tracers [33]. This
is why there has been an ongoing development to
standardise quantitative Aβ imaging measures using
the “centiloid scale” [34]. Work is now ongoing to
validate centiloid scaling between various tracers and
against other biomarkers [35–37]. Standardisation
such as centiloid scaling has yet to be applied in tau
imaging to a greater extent [38].
As post mortem and in vivo biomarker evidence
closely associate Aβ pathology with AD, Aβ PET
tracers have become standard tools for clinicians to
aid in their diagnosis of patients suspected of having
AD [39]. These tracers also have a key place in AD
research in differentiating diagnostic groups and
tracking disease progression [40]. In addition, these
tracers are readily used for the evaluation of thera-
peutic trial outcomes to examine the effects of drugs
removing brain Aβ [41, 42].
Tau PET
The advent of tau-specific PET tracers has marked the
beginning of a new era with potential applications in dif-
ferential diagnosis and prognosis and serving as a sec-
ondary outcome measure for clinical trials [43]. Tau is
physiologically involved in the stabilisation of microtu-
bules and can present with three or four repeat (3R/4R)
microtubule-binding domains [44, 45]. First-generation
tau PET ligands all seem to bind mixed 3R/4R paired
helical filament (PHF) formations of tau [46–50] and
include [11C]PBB3, a series of “THK” tracers
([18F]THK523, [18F]THK5105 and [18F]THK5351), and
[18F]flortaucipir (formerly [18F]T807 or [18F]AV1451)
[51–53]. As these “first-generation” tracers face chal-
lenges such as off-target binding, novel tau compounds
have been developed, though their relationship with clin-
ical outcome measures has yet to be established in larger
cohorts [54, 55]. Notable “second-generation” tau li-
gands include [18F]RO948, [18F]GTP1, [18F]PI2620,
[18F]PM-PBB3 and [18F]MK6240 [54, 56–60], which
have shown reduced off-target binding with similar on-
target signal response [61, 62]. As currently available tau
PET ligands bind AD-like mixed 3R/4R tau pathology,
the utility of tau PET in pure 3R or 4R tauopathies, such
as progressive supranuclear palsy and corticobasal de-
generation, has shown to be less persuasive [57]. So far,
tau PET studies in clinical settings have mostly been
performed within the field of AD using the [18F]flortau-
cipir tracer (see Fig. 1).
In AD, tau PET imaging studies have demonstrated
that tau deposition seems to follow the staging pattern
revealed by Braak and Braak, suggesting tau spreads
from the entorhinal cortex (Braak I/II) to the inferolat-
eral temporal and medial parietal lobes (Braak III/IV)
and finally the neocortex (Braak V/VI) [63–65]. This
vulnerability of brain regions for tau pathology overlaps
with brain regions underlying the different clinical phe-
notypes in typical and atypical AD dementia and corre-
lates with atrophy and reduced glucose metabolism in
those regions, a relationship that is not found with Aβ
[66, 67]. Tau pathology in Braak I/II is also commonly
observed in cognitively unimpaired controls, which likely
reflects an age-related process of tau accumulation. Also,
in these cognitively unimpaired individuals, tau seems to
be associated with regional atrophy and hypometabo-
lism, as well as to subtle cognitive deficits [68–73]. Fur-
thermore, a recent longitudinal study has shown that
both baseline and change in [18F]flortaucipir are related
to changes in cognition [74]. Hence, both the amount
and distribution of tau PET accurately reflect cognitive
symptoms and deterioration. The clinical utility of tau
PET has recently been demonstrated in a multi-centre
study highlighting the ability of [18F]flortaucipir to dis-
criminate between AD dementia and non-AD
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neurodegenerative diseases, with highest sensitivity
(96.8%) and specificity (87.9%) using several thresholds
applied to temporal and temporoparietal regions [75].
Furthermore, while tau PET and tau measured in the
cerebrospinal fluid (CSF) performed equally well in sep-
arating prodromal AD from controls, tau PET outper-
formed tau-CSF in discriminating prodromal AD from
AD dementia [76].
Although tau PET imaging shows great potential for
implementation into the clinic, the high regional specifi-
city of tau requires careful selection of regional and
global measures for categorising individuals into tau-
positive or tau-negative as suggested by the NIA-AA re-
search framework. Different cut points for tau-tracer
binding in different brain regions have been suggested,
however, standardisation of such methodological aspects
is needed. Furthermore, although the majority of AD pa-
tients present with both high Aβ and high tau burden,
studies have shown that some AD patients present with
high Aβ and low tau burden [77–79]. Possible explana-
tions such as clinical misdiagnoses (with incidental Aβ
co-pathology) or differences in tau conformations that
might affect tracer binding are to be examined in future
clinical tau PET studies and studies using novel tau PET
ligands. Importantly, although the advent of tau PET
tracers has greatly advanced our knowledge regarding
the close relationship between tau pathology and down-
stream neurodegeneration events linked to cognitive de-
cline, it remains as of yet unknown how Aβ relates to
the development of tau, and how tau relates to the oc-
currence of neurodegeneration. A study by Jacobs and
colleagues indicated that Aβ may facilitate the spread of
tau from the medial temporal lobe to the downstream
posterior cingulate cortex through the parahippocampal
cingulum [80]. Ideally, multimodal longitudinal imaging
studies are needed to elucidate the temporal relation-
ships between pathology biomarkers.
SV2A PET
In AD, Aβ and tau alongside neuroinflammation and
vascular insufficiency lead to irreversible synaptic dys-
function and loss [81] causing the deleterious amnestic
presentation of the disease. Loss of synapses and de-
creased synaptic density (particularly the vulnerable
hippocampus/medial temporal lobe) are likely earlier
events than neurodegeneration and important for drug
targets. Previously, synaptic density changes could only
be studied cross-sectionally from post mortem brain tis-
sue or biopsy [82, 83]. Recently, these changes have been
able to be visualised directly in vivo in humans [84].
PET ligands targeting the synaptic vesicle glycoprotein
2A (SV2A) form a potentially useful and exciting investi-
gative tool to measure synapses [85]. SV2 is a 12 trans-
membrane domain integral protein with three isoforms
(2A, 2B and 2C). SV2A is the most ubiquitous and is
expressed as a transmembrane glycoprotein in
secretory vesicles on presynaptic terminals. It is crit-
ical to synaptic function, particularly Ca2+-dependent
exocytosis [86], and is known to be the binding site
of levetiracetam [87].
[11C]UCB-J is a PET ligand developed to image SV2A
with favourable brain uptake, kinetics and dosimetry
shown in non-human primates [88]. There is a high cor-
relation between in vitro SV2A UCB-J binding and
in vitro synaptophysin density (r2 = 0.90 for GM regions)
pre-clinically [4]. [11C]UCB-J has a high affinity for
SV2A (Ki = 7 nm) and has been successfully displaced by
levetiracetam in vivo in humans, with good dosimetry
Fig. 1 Comparison of [18F]florbetaben and [18F]flortaucipir for three patients. The authors would like to acknowledge Dr. Susan Landau (UC
Berkeley) for her assistance in the creation of this figure. Scale is standardised uptake value ratio (SUVr)
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(4.5 mSv/MBq) [4]. Regional time-activity curves showed
[11C]UCB-J has fast kinetics, was well described by a 1
tissue compartment model (1TC) or a simplified refer-
ence tissue model (SRTM) (reference centrum semi-
ovale) and had a 3–9% mean test-retest variability in VT
across regions [89].
Decreased [11C]UCB-J binding was first shown in a
small disease group with temporal lobe epilepsy and me-
sial temporal sclerosis (n = 3), revealing region-specific
unilateral decreases in the hippocampus [84]. The first
study in MCI/AD using [11C]UCB-J compared Aβ+ pa-
tients (n = 10) with age-matched Aβ− controls and
showed a significant reduction in hippocampal SV2A
binding (41% decrease in BPND) that survived partial vol-
ume correction and correlated significantly with episodic
memory [89]. The decrease in SV2A binding throughout
the neocortex in MCI/AD was modest and not signifi-
cantly different from controls.
Multiple other candidates selective to SV2A have
been developed including [18F]UCB-H, which dis-
plays a comparatively good signal but higher
variability than [11C]UCB-J [90] and a human
dosimetry of 19.7mSv/MBq [91]. The longer [18F] half-
life allows wider use and more time for transit to clinical/
research sites [92].
Much future work involving SV2A imaging in AD re-
mains. Currently, the first published AD study needs
replication with more patients alongside longitudinal in-
vestigation. The relationship of SV2A binding with Aβ/
tau needs to be explored as well as its relationship with
other disease features such as mitochondrial dysfunction,
cellular stress and glial (microglial and astrocyte) reactiv-
ity. A summary of discussed PET imaging can be found
in Table 1.
Magnetic Resonance Imaging
Structural MR imaging
Structural imaging is the imaging workhorse of neurode-
generation, it is the most widely used and accessible, it is
recommended in diagnostic guidelines [101] and it
forms part of most consensus criteria. Structural MRI
(sMRI) has several advantages over computed tomog-
raphy (CT). Its main uses are (a) excluding brain lesions,
(b) determining patterns of atrophy and (c) assessing
vascular burden. Research key aims include improving
early diagnosis and tracking disease progression.
Table 1 Summary table of typical PET tracers for neurodegeneration-related investigations discussed in this article
Example tracers Protocol Analysis Limitations
Glucose
metabolism:
[18F]FDG
• Fasting for ~ 4 h
• Scanning 30 min after injection
• Scan typically for 0–30min
• SUV using weight and injected dose
• SUVR using cerebellar grey matter or pons
as reference regions [7]
• Hypometabolic patterns overlap
between multiple
neurodegenerative diseases [8–10]
• Still not enough evidence to
support routine clinical use in the
prodromal phase [93]
Aβ:
[11C]PiB
[18F]Florbetaben
[18F]Florbetapir
[18F]Flutametamol
[18F]NAV4694
Scan protocols vary between tracers;
however, typically, patients are scanned
40–60min (PiB) or 70–90min (most [18F]-
based tracers) after injection for ~ 20 min.
For EANM clinical guidelines, see
Minoshima et al. [94]
Typical analysis will use SUVR using the
cerebellum or cerebellar grey matter as the
reference region [21, 31, 32]
• [C11]PiB requires an on-site
cyclotron
• Second-generation tracers have cer-
tain off-target binding issues as well
as reduced uptake in the cortex as
compared to PiB [30]
• Latest generation tracers have yet to
be validated in larger cohorts
• Aβ positivity can refer to various
neurodegenerative diseases [95]
Tau:
[18F]THK5351
[18F]THK5317
[18F]THK523
[11C]PBB3
[18F]Flortaucipir
[18F]RO948
[18F]MK6240
[18F]GTP1
[18F]PI2620
Scan protocols vary between tracers;
however, typically, patients are scanned in
the range of 50–90 min after injection for
~ 20min [96]
Most typical analyses will derive SUVR using
the cerebellum, cerebellar grey matter or
inferior cerebellum/cerebellar grey as the
reference region [96].
• Molecular diversity of tauopathies
means no single tau tracer can be
used for all disorders [57]
• First-generation tracers exhibit off-
target binding and subcortical white
matter uptake [96, 97]
• Second-generation ligands have yet
to be evaluated with regard to clin-
ical outcomes in larger cohorts [54,
55, 96]
• Experimental and clinical validation
of tau tracers in general is still
required [98, 99]
SV2A:
[11C]UCB-J
[18F]UCB-H
Scan protocols are yet to be determined in
more studies using SV2A PET tracers
Centrum semi-ovale is most commonly
used as the reference region, despite some
evidence of synaptic changes [100]. Re-
cently, also a cerebellar reference region
has been suggested.
• Requires replication with more
patients alongside longitudinal
investigation [84, 89]
• Association with other disease
features (as described above) needs
to be explored
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Atrophy patterns—signatures of neurodegeneration
Neurodegenerative disorders, to a greater or lesser ex-
tent, show characteristic patterns or signatures of brain
atrophy on T1-weighted images (see Fig. 2) that can be
used to improve differential diagnosis. Table 2 outlines
some of the most common and useful atrophy patterns
for the diagnosis of these diseases. Specific brain signa-
tures have also been described in young onset AD [102,
103] and genetically mediated forms of frontotemporal
dementia [104–106].
It is also important to mention the utility of white
matter hyperintensities (WMH) as these are essen-
tial for the diagnosis of cerebral small vessel disease
(CSVD) [107]. Moreover, the location of micro-
bleeds seen with T2*/SWI sequences can often
bring diagnostic clarity on the underlying path-
ology—microbleeds associated with hypertension are
found in deep brain regions, whereas Aβ-related
microbleeds are more likely cortical [108]. Finally,
diffusion-weighted imaging is the most sensitive
sequence in the diagnosis of sporadic Creutzfeldt-Jakob
disease [109].
Current use of structural MRI in research
Voxel-wise analyses confirm the value of brain atrophy
patterns in pathologically distinct dementias [117–119].
In AD, volume loss appears later than Aβ deposition
and synaptic dysfunction [120], but hippocampal
changes are detected before symptoms [121]. Further-
more, hippocampal volume has been validated and ac-
cepted by regulatory agencies as a biomarker for trials
targeting predementia stages [122]. Longitudinal rates of
atrophy monitor progression and can change the sample
size needed to show treatment effects depending on the
technique and selected anatomical region [123, 124].
Cortical thickness has also been shown to be a marker
of AD, where regionally specific cortical thinning can be
used to detect presymptomatic Aβ-positive individuals but
also can indicate the severity of symptoms [125, 126]. It
has also been shown to be able to differentiate between
neurodegenerative disorders, for example between AD
and FTD [127]. Shape analysis can also be used in
differentiating individuals, studies of hippocampal shape
changes and atrophy have demonstrated differences in
the substructural changes of the hippocampus
Table 2 Atrophy patterns included in the current diagnostic criteria of selected neurodegenerative dementias. Only changes in T1-
weighted MRI sequence are included in the MRI signature column. The MRI signatures described are supportive features for the
diagnosis unless otherwise stated. PPA primary progressive aphasia. FTD frontotemporal dementia
Disease Diagnostic criteria MRI signature
Alzheimer’s disease McKhann et al. [110] Disproportionate atrophy in the medial, basal and lateral temporal lobe and medial parietal
cortex
Posterior cortical atrophy Crutch et al. [111] Predominant occipito-parietal or occipito-temporal atrophya
Logopenic variant PPA Gorno-Tempini et al.
[112]
Predominant left posterior perisylvian or parietal atrophy
Behavioural variant FTD Rascovsky et al. [113] Frontal and/or anterior temporal atrophy
Semantic variant PPA Gorno-Tempini et al.
[112]
Predominant anterior temporal lobe atrophy
Non-fluent variant PPA Gorno-Tempini et al.
[112]
Predominant left posterior fronto-insular atrophy
Dementia with Lewy bodies McKeith et al. [114] Relative preservation of the medial temporal lobe structuresb
Multiple system atrophy Gilman et al. [115] Atrophy of the putamen, middle cerebellar peduncle, pons or cerebellum
Progressive supranuclear
palsy
Höglinger et al. [116] Atrophy predominant in the midbrain relative to pons
aCore neuroimaging feature of the PCA clinico-radiological syndrome; bnon-specific biomarker for DLB, but useful to differentiate from AD
Fig. 2 T1-weighted MRI scans demonstrating characteristic cortical atrophy signature in selected diseases: a typical amnestic Alzheimer’s disease,
b posterior cortical atrophy, c behavioural variant frontotemporal dementia and d semantic dementia
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depending on the type of neurodegenerative disorder
[126, 128]. Shape analysis of brain ventricles has also
shown that markers such as perimeters of the ventricles
can be simple markers extracted from sMRIs to differen-
tiate HC and AD [129].
Future directions of research
High-resolution volumetry of the medial temporal
lobe in AD using 7T MRI High spatial resolution sMRI
now allows for volumetry of hippocampal subfields [130,
131]. Early changes in CA1 have been observed in AD,
with volumetric studies indicating that CA1 atrophy
measures may improve diagnostic accuracy at the MCI
stage (see [120] for a review). Other studies, however,
have found that the subiculum is associated with poorer
cognitive performance and risk of developing dementia
[132] and may serve as an early marker of AD-related at-
rophy [133]. Recent studies of volume, thickness and
shape measurements of extrahippocampal subregions in
the medial temporal lobe have shown that thickness
measurements of the transentorhinal region could differ-
entiate Aβ positive from negative individuals while out-
performing other measures such as CA1 or whole
hippocampal volume [134].
Assessment of iron deposition using in vivo MRI
Novel MRI techniques, such as quantitative susceptibility
mapping (QSM) or the T2* transverse relaxation time,
have shown that iron levels and its rate of accumulation
are heterogeneous in the human brain [135] and corre-
lates with cognitive impairment [136, 137] and slowing
of motor performance [138, 139]. Abnormal iron depos-
ition has been reported in AD [140, 141], Parkinson’s
disease (PD) (for a review see [142]), multiple sclerosis
[143, 144] and additional neurodegenerative disorders
(for a review see [145]). The elevation in cortical iron
deposition in PD is concordant with known alpha-
synuclein pathology [146] and in AD, has been shown to
predict cognitive decline in individuals with Aβ path-
ology [147].
Taken together, in vivo sMRI techniques may have the
potential to improve early and differential diagnosis, aid
stratification of patients into clinical trials and track
disease progression in neurodegenerative disorders.
Functional MRI, ASL, DTI and graph theory
Functional MRI
Neuronal dysfunction and altered connectivity of distinct
brain networks are thought to occur early in the course
of neurodegenerative diseases and can be measured in-
directly with functional magnetic resonance imaging
(fMRI). In AD, several resting-state fMRI studies re-
vealed altered connectivity in the default mode network
[148, 149], ranging from hippocampal coactivation [150]
to potential compensatory increased activation in the
MTL [151]. Studies have also suggested distinct atrophy
patterns within various intrinsic functional networks for
a number of neurodegenerative diseases [152]. Task-
based fMRI studies are less consistent and have often re-
ported increased task activation or reduced deactivation
in hippocampus, frontal and parietal regions in the pres-
ence of AD pathology or in patients with MCI (e.g.
[153–158]). There are also data indicating that an initial
phase of hyperactivation [159] is followed by hypoactiva-
tion with further increasing Aβ burden and disease pro-
gression [160, 161]. Whether task-based fMRI shows
hyper- or hypoactivation likely depends on the specific
fMRI contrast/task, the brain region examined, and the
pathological stage of an individual (for an example see
Fig. 3). While task-based fMRI is a promising future bio-
marker, sensitivity and reliability of different fMRI tasks
within-subject and across cohorts still need to be
established.
Arterial Spin Labelling
Current models of AD suggest that metabolic alterations
occur in the brain before structural changes could be
identified. FDG PET (as discussed earlier) has been a
standard tool for measuring these changes in the past;
however, due to the introduction of tau and Aβ-specific
PET tracers (as discussed previously), there is increased
demand for a biomarker that does not require a second
PET scan. Arterial spin labelling (ASL) has shown to be
a promising replacement for FDG PET; this is due to the
metabolism and perfusion in the brain being very closely
matched [162] and so hypometabolic patterns seen in
FDG PET can be equally seen in ASL images. This fact
coupled with patients already undergoing an MRI scan
means that ASL could serve as a cheaper and faster
alternative which would also reduce the radiation burden
to the patient without sacrificing any diagnostic quality
for both AD and FTD [163, 164]. For both AD and other
neurodegenerative diseases, there is still a requirement
for larger studies to validate this technique [163, 165].
DTI
The brain’s white matter tracts are also sensitive to the
underlying pathology of neurodegenerative disease [166,
167]. Using diffusion tensor imaging (DTI), a variant of
MRI that is sensitive to the mobility of water molecules
in tissue, it is possible to quantify the microstructural
properties of white matter tracts in vivo [168]. In AD,
DTI studies have identified microstructural alterations
(specifically increased absolute diffusivities and reduced
fractional anisotropy) in tracts linking regions affected
early by disease pathology, including the fornix, para-
hippocampal cingulum and corpus callosum [169–171].
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Microstructural variation in these tracts has also been
associated with the accumulation of Aβ and tau in cog-
nitively normal individuals [80, 172], suggesting that
DTI may prove useful as a biomarker for AD. Similarly,
alterations in diffusivity have been described in pre-
symptomatic and early-stage familial frontotemporal
dementia. Individuals suffering from amyotrophic lateral
sclerosis (ALS) were also seen to have increased diffusiv-
ity in the bilateral centrum semi-ovale as well as deep
and parietal white matter [173]. However, common DTI
measures such as fractional anisotropy are influenced by
numerous disease-relevant properties, including myelin-
ation, thereby limiting anatomical specificity [174]. Thus,
while DTI has proven to be useful as a tool for under-
standing neurodegenerative conditions, further research
is needed to establish its utility as a biomarker.
Graph theory
Graph theory is the study of systems of interactive ele-
ments—‘nodes’, and the connections between them—
‘edges’ [175, 176], allowing for representation of brain
networks. Both structural (DTI) and functional connect-
ivity measures (fMRI) can be obtained from brain graphs
[177, 178]. AD research uses graph theory to examine
integration (path length between nodes), segregation
(clustering) and centrality (importance of nodes in a net-
work) [179]. Network topology appears to be disrupted,
with clinical symptoms arising from changes in commu-
nication between anatomically and functionally con-
nected brain areas [179]. AD appears to result in longer
paths between nodes with lower global efficiency [179]
and with less interconnectivity and more segregated
clusters in the default mode network (DMN) [180].
Widespread changes within and outside the DMN are
seen with advanced Aβ accumulation [181]. Inconsistent
findings between AD studies may be due to different
definitions of nodes and edges [182]. Harmonisation is
needed for future work.
Machine learning
Current reviews of ML algorithms applied to neurode-
generative disorders include a systematic review of the
use of ML and neuroimaging in general to assist the
diagnosis of dementia [183, 184] to more methodological
reviews, focusing on feature extraction, different ML ar-
chitectures and validation techniques [185–187]. Three
Fig. 3 Cognitively normal older adults (n = 49) underwent 3-T fMRI while performing a mnemonic discrimination task as well as PET imaging. A
whole-brain multiple regression showed that increased tau burden (mean flortaucipir SUVR from Braak III/IV ROI) was related to increased task
activation during object processing (covarying for age and gender). Tau-related activation increases were seen mainly in hippocampus and
posterior-medial regions. Results are FDR-corrected at the cluster level (pcluster < .05, pvoxel < .001 uncorrected). The scatter plot (lower left) shows
the correlation of regional Flortaucipir SUVR and object activation in posterior-medial regions. See Maass et al. [158] for study details
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longitudinal studies analysed the progression of AD
[188–190] using structural MRI and deep learning (DL)
algorithms such as recurrent neural networks (RNNs)
and variations of long short-term memory networks
(LSTMN). The most common feature in order to study
disease progression is hippocampal volume.
Early diagnosis and progression to MCI/AD
The majority of ML studies are focused on diagnosis or
early detection of AD [191–213]. There has been an in-
creasing effort to try to fully predict AD from MCI or
healthy controls as well as using artificial intelligence
techniques (such as ML or DL) in order to aid clinical
diagnosis. Lately, more importance has been given to
subject memory complaints (SMC) as it could be a pre-
asymptomatic stage of MCI.
There are several longitudinal databases that are help-
ing to develop these kinds of studies such as ADNI,
OASIS or the Rotterdam Study. With this increase of
data, there has been a shift from the use of ML algo-
rithms such as support vector machines (SVMs) and k
nearest neighbours (KNN) to more DL-based studies,
mostly convolutional neural networks (CNNS) [205, 214,
215]. Along with feature selection methods, these
models combine different sMRI cortical and subcortical
volumetric measures to identify disease subtypes [216].
Neural networks (NNs) based on sMRI and cognitive
scores can predict the conversion of MCI to AD
(cMCI) and distinguish between stable MCI and
cMCI [214, 217, 218]. ML classifiers can also differen-
tiate between clinical syndromes of frontotemporal
dementia (FTD) [219]. Longitudinal studies using fea-
ture extraction-based learning techniques provide im-
proved atrophy measures with significantly lower
mean absolute error and volumetric markers such as
the hippocampus, posterior cingulate cortex and
middle temporal gyrus for evaluating disease progression
in AD and MCI [190, 220, 221].
Multimodal machine learning
ML is an optimal approach to combine the findings of
different imaging modalities. NNs based on grey matter
density from MRI and glucose metabolism from PET
yields better results than individual modalities [215, 222,
223]. Structural and connectivity measures from MRI
combined with metabolism rate from PET predict the
conversion of MCI to AD. Deep learning models can
predict cMCI from non-white matter extractions using
PET images combined with MRI images. NNs based on
sMRI or resting-state fMRI, cognitive and functional as-
sessments show enhanced automatic diagnosis of both
AD and MCI [224]. ML techniques can be used to
combine clinical measures with multiple imaging modal-
ities to understand the neuropathological processes of
diseases [225].
Fig. 4 The imaging arm (red) as part of the greater collaborative approach to neurodegeneration [226]
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Conclusion
There is a growing body of evidence that imaging bio-
markers can be useful in the detection and monitoring
of neurodegenerative diseases. Due to the complexity of
many of the diseases being studied as well as a variation
in the results reported, extracting definitive findings re-
mains a challenge. With ongoing and planned trials for
various treatments, it is important to incorporate im-
aging biomarkers into these trials as well as continuing
to improve the diagnostic and prognostic power of these
techniques. On a wider scale, imaging biomarkers have a
part to play in a collaborative approach to neurodegen-
eration (Fig. 4) as understanding and treatment becomes
increasingly multidisciplinary.
Abbreviations
1TC: 1 tissue compartment (model); AD: Alzheimer’s disease; ASL: Arterial
spin labelling; Aβ: Amyloid-beta; cMCI: Converting mild cognitive
impairment; CSF: Cerebrospinal fluid; CSVD: Cerebral small vessel disease;
CT: Computed tomography; DLB: Dementia with Lewy bodies; DMN: Default
mode network; DTI: Diffusion tensor imaging; FDG: 2-Fluoro-2-deoxy-D-
glucose; fMRI: Functional magnetic resonance imaging; FTD: Frontotemporal
dementia; KNN: k nearest neighbour; LSTMN: Long short-term memory net-
work; MCI: Mild cognitive impairment; MRI: Magnetic resonance imaging;
NFT: Neurofibrillary tangle; NN: Neural network; PD: Parkinson’s disease;
PET: Positron emission tomography; PHF: Paired helical filament;
PiB: Pittsburgh compound B; QSM: Quantitative susceptibility mapping;
RNN: Recurrent neural network; SMC: Subject memory complaints;
sMRI: Structural magnetic resonance imaging; SRTM: Simplified reference
tissue model; SUV: Standardised uptake value; SUVR: Standardised uptake
value ratio; SV2A: Synaptic vesicle glycoprotein 2A; SVM: Support vector
machines; WMH: White matter hypointensities
Acknowledgements
This research did not receive any specific grant from funding agencies in the
public, commercial or not-for-profit sectors.
Authors’ contributions
PY, ME, EC, MS, HB, MB, AM, AV, RL, DJ, EM and DB wrote the manuscript.
AO, NF, JP, WJ, SC, RP and MS critically reviewed the manuscript. The authors
read and approved the final manuscript.
Authors’ information
This review article is part of a series of articles that has stemmed from the
“Biomarkers in neurodegenerative disease” 2019 course run collaboratively
between UCL and the University of Gothenburg. The attendees of this
course have authored this article with the presenters of this course critically
reviewing their work.
Funding
The UCL Biomedical Research Centre (BRC) provided funding for the
“Biomarkers in neurodegenerative disease” course that this review is based
on. Open access funding provided by the University of Gothenburg.
Availability of data and materials
This review does not contain any analysable data. All sources cited in this
paper are publicly available.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors have no conflicts of interest to disclose.
Author details
1Wallenberg Centre for Molecular and Translational Medicine and the
Department of Psychiatry and Neurochemistry, University of Gothenburg,
Sahlgrenska University Hospital, Gothenburg, Sweden. 2Centre for Medical
Image Computing (CMIC), Department of Computer Science & Department
of Medical Physics and Biomedical Engineering, University College London,
London, UK. 3Department of Radiology and Nuclear Medicine, Amsterdam
Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam,
Netherlands. 4Neuroscience and Aphasia Research Unit, Division of
Neuroscience and Experimental Psychology, The University of Manchester,
Manchester, UK. 5German Center for Neurodegenerative Diseases (DZNE),
Magdeburg, Germany. 6Division of Brain Sciences, Imperial College London,
London, UK. 7United Kingdom Dementia Research Institute, Imperial College
London, London, UK. 8Cardiff University Brain Research Imaging Centre
(CUBRIC), School of Psychology, Cardiff, UK. 9Dementia Research Centre, UCL
Institute of Neurology, University College London, London, UK. 10Department
of Neurological Sciences, Faculty of Medicine, University of Chile, Santiago,
Chile. 11Institute of Cognitive Neurology and Dementia Research,
Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. 12Trinity
College Dublin, The University of Dublin, Dublin, Ireland. 13Clinical Memory
Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund,
Sweden. 14Division of Clinical Geriatrics, Department of Neurobiology, Care
Sciences and Society, Karolinska Institutet, Stockholm, Sweden. 15Helen Wills
Neuroscience Institute, University of California, Berkeley, USA. 16Molecular
Biophysics and Integrated Bioimaging, Lawrence Berkeley National
Laboratory, Berkeley, CA, USA. 17Department of Psychiatry, School of Clinical
Medicine, University of Cambridge, Cambridge, UK. 18Wolfson Molecular
Imaging Centre, Division of Neuroscience and Experimental Psychology,
MAHSC, University of Manchester, Manchester, UK. 19Department of Clinical
Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Received: 24 October 2019 Accepted: 1 April 2020
References
1. Douaud G, Refsum H, de Jager CA, Jacoby RE, Nichols T, Smith SM, et al.
Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin
treatment. Proc National Acad Sci. 2013;110(23):9523 Available from: http://
www.pnas.org/content/110/23/9523.abstract.
2. Jack CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron.
2013;80(6):1347–58 [cited 2019 Aug 15] Available from: http://www.ncbi.
nlm.nih.gov/pubmed/24360540.
3. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.
NIA-AA Research Framework: toward a biological definition of Alzheimer’s
disease. Alzheimer’s Dementia. 2018;14(4):535–62 Available from: https://
www.ncbi.nlm.nih.gov/pubmed/29653606.
4. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic
measurement of local cerebral glucose metabolic rate in humans with (F-
18)2-fluoro-2-deoxy-D-glucose: validation of method. Annals Neurol. 1979;
6(5):371–88 [cited 2019 Aug 15] Available from: http://www.ncbi.nlm.nih.
gov/pubmed/117743.
5. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al.
FDG PET imaging in patients with pathologically verified dementia. J
Nuclear Medicine. 2000;41(11):1920–8 Available from: http://jnm.
snmjournals.org/content/41/11/1920.abstract.
6. Rocher AB, Chapon F, Blaizot X, Baron J-C, Chavoix C. Resting-state brain
glucose utilization as measured by PET is directly related to regional
synaptophysin levels: a study in baboons. NeuroImage. 2003;20(3):1894–8
[cited 2019 Aug 15] Available from: http://www.ncbi.nlm.nih.gov/
pubmed/14642499.
7. Tada T, Hasegawa C, Odagawa T, Abe S, Kato K. Comparative examination
of the cerebellum and pons as reference regions for quantitative evaluation
in PET imaging for Alzheimer’s disease using11C-Pittsburgh Compound-B.
Journal of Nuclear Medicine. 2019;60(supplement 1):3012. Available from:
http://jnm.snmjournals.org/content/60/supplement_1/3012.abstract.
8. Brown RKJ, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in
suspected dementia: patterns of altered FDG metabolism. Radiographics.
34(3):684–701 [cited 2019 Aug 15] Available from: http://www.ncbi.nlm.nih.
gov/pubmed/24819789.
9. Herholz K, Haense C, Gerhard A, Jones M, Anton-Rodriguez J, Segobin S, et al.
Metabolic regional and network changes in Alzheimer’s disease subtypes. J
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 10 of 17
Cerebral Blood Flow Metabolism. 2018;38(10):1796–806 [cited 2019 Aug
15]Available from: http://www.ncbi.nlm.nih.gov/pubmed/28675110.
10. Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical
utility of FDG-PET for the differential diagnosis among the main forms of
dementia. Eur J Nuclear Med Mol Imaging. 2018;45(9):1509–25 Available
from: https://doi.org/10.1007/s00259-018-4035-y.
11. Mosconi L, Berti V, Glodzik L, Pupi A, de Santi S, de Leon MJ. Pre-clinical
detection of Alzheimer’s disease using FDG-PET, with or without amyloid
imaging. J Alzheimer’s Disease. 2010;20:843–54.
12. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C.
18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and
other dementias in people with mild cognitive impairment (MCI). Vol. 2017,
Cochrane Database of Systematic Reviews. Wiley; 2015.
13. Anazodo UC, Finger E, Kwan BYM, Pavlosky W, Warrington JC, Günther M,
et al. Using simultaneous PET/MRI to compare the accuracy of diagnosing
frontotemporal dementia by arterial spin labelling MRI and FDG-PET.
NeuroImage Clin. 2018;17:405–14 [cited 2019 Aug 15] Available from: http://
www.ncbi.nlm.nih.gov/pubmed/29159053.
14. Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla
AJ, et al. 18F-FDG PET in posterior cortical atrophy and dementia with Lewy
bodies. J Nuclear Med. 2017;58(4):632–8 [cited 2019 Aug 15] Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27688479.
15. Sprinz C, Altmayer S, Zanon M, Watte G, Irion K, Marchiori E, et al. Effects of
blood glucose level on 18F-FDG uptake for PET/CT in normal organs: a
systematic review. PloS One. 2018;13(2):e0193140 Available from: https://
www.ncbi.nlm.nih.gov/pubmed/29486008.
16. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Mol Med. 2016;8(6):595–608 Available from: https://www.ncbi.
nlm.nih.gov/pubmed/27025652.
17. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization
of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals:
evidence that an initially deposited species is Aβ42(43). Neuron. 1994;13(1):
45–53 [cited 2019 Aug 15] Available from: https://www.sciencedirect.com/
science/article/pii/0896627394904588.
18. Krause DL, Müller N. Neuroinflammation, microglia and implications for
anti-inflammatory treatment in Alzheimer’s disease. Int J Alzheimer’s
Disease. 2010;2010:732806 Available from: https://www.ncbi.nlm.nih.gov/
pubmed/20798769.
19. Mokhtar SH, Bakhuraysah MM, Cram DS, Petratos S. The beta-amyloid
protein of Alzheimer’s disease: communication breakdown by modifying
the neuronal cytoskeleton. Int J Alzheimer’s Dis. 2013;2013:910502 Available
from: https://www.ncbi.nlm.nih.gov/pubmed/24416616.
20. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET
of brain amyloid and tau in mild cognitive impairment. New England J
Med. 2006;355(25):2652–63 Available from: https://doi.org/10.1056/
NEJMoa054625.
21. Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo
staging of regional amyloid deposition. Neurology. 2017;89(20):2031–8
Available from: https://www.ncbi.nlm.nih.gov/pubmed/29046362.
22. Edmonds EC, Bangen KJ, Delano-Wood L, Nation DA, Furst AJ, Salmon DP,
et al. Patterns of cortical and subcortical amyloid burden across stages of
preclinical Alzheimer’s disease. J Int Neuropsychol Soc. 2016;22(10):978–90
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27903335.
23. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ,
et al. Comparing positron emission tomography imaging and cerebrospinal
fluid measurements of β-amyloid. Ann Neurol 2013;74(6):826–36. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/23536396.
24. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC,
Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid
imaging in a typical case of Alzheimer’s disease. Brain. 2008/03/12. 2008
131(Pt 6):1630–45. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/18339640.
25. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.
Imaging brain amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Ann Neurol. 2004;55(3):306–19. Available from: https://doi.
org/10.1002/ana.20009.
26. Nelissen N, van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M,
et al. Phase 1 study of the Pittsburgh compound B derivative 18F-
flutemetamol in healthy volunteers and patients with probable Alzheimer
disease. J Nuclear Med. 2009;50(8):1251–9 Available from: http://jnm.
snmjournals.org/content/50/8/1251.abstract.
27. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid
imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh
compound-B positron emission tomography. Journal of neurology,
neurosurgery, and psychiatry. 2012/07/11. 2012;83(9):923–6. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/22791901.
28. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical
properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. Journal
of nuclear medicine : official publication, Society of Nuclear Medicine. 2009/
10/16. 2009;50(11):1887–94. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/19837759.
29. Ikonomovic MD, Buckley CJ, Heurling K, Sherwin P, Jones PA, Zanette M,
et al. Post-mortem histopathology underlying β-amyloid PET imaging
following flutemetamol F 18 injection. Acta Neuropathologica
Communications. 2016;4(1):130. Available from: https://doi.org/10.1186/
s40478-016-0399-z.
30. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-
to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid
imaging in aging and dementia. J Nuclear Med. 2013;54(6):880–6 Available
from: http://jnm.snmjournals.org/content/54/6/880.abstract.
31. Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, et al.
Optimal reference region to measure longitudinal amyloid-β change with
18F-Florbetaben PET. J Nuclear Medicine. 2017;58(8):1300–6 Available from:
http://jnm.snmjournals.org/content/58/8/1300.abstract.
32. Chiao P, Bedell BJ, Avants B, Zijdenbos AP, Grand’Maison M, O’Neill P, et al.
Impact of reference and target region selection on amyloid PET SUV ratios in
the phase 1b PRIME study of aducanumab. J Nuclear Medicine. 2019;60(1):
100–6 Available from: http://jnm.snmjournals.org/content/60/1/100.abstract.
33. Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al.
Defining imaging biomarker cut points for brain aging and Alzheimer’s
disease. Alzheimer’s & Dementia. 2017;13(3):205–16 Available from: http://
www.sciencedirect.com/science/article/pii/S1552526016328758.
34. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ,
et al. The Centiloid Project: standardizing quantitative amyloid plaque
estimation by PET. Alzheimer’s & dementia : the journal of the Alzheimer’s
association. 2014/10/28. 2015 Jan;11(1):1-15.e154. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/25443857.
35. Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-
Calvet M, et al. Centiloid cut-off values for optimal agreement between PET
and CSF core AD biomarkers. Alzheimer’s Research & Therapy. 2019;11(1):27.
Available from: https://doi.org/10.1186/s13195-019-0478-z.
36. Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, et al.
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET
studies. NeuroImage Clinical. 2018 ;19:406–16. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/30035025.
37. Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid
scaling for quantification of brain amyloid with [(18)F]flutemetamol using
multiple processing methods. EJNMMI research. 2018;8(1):107. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/30519791.
38. Yamao T, Miwa K, Matsuda H, Akamatsu G, Wagatsuma K, Takano H.
Feasibility of 18F-THK5351 PET quantitation using the Centiloid scale.
Journal of Nuclear Medicine. 2019;60(supplement 1):1182. Available from:
http://jnm.snmjournals.org/content/60/supplement_1/1182.abstract.
39. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P,
et al. Revising the definition of Alzheimer’s disease: a new lexicon. The Lancet
Neurology. 2010 [cited 2019 Aug 15];9(11):1118–27. Available from: https://www.
sciencedirect.com/science/article/pii/S1474442210702234?via%3Dihub.
40. Vandenberghe R, Adamczuk K, Dupont P, Laere K van, Chételat G. Amyloid
PET in clinical practice: its place in the multidimensional space of
Alzheimer’s disease. NeuroImage Clinical. 2013;2:497–511. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/24179802.
41. Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, et al. Central
review of amyloid-related imaging abnormalities in two phase III clinical
trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
patients. Journal of Alzheimer’s disease : JAD. 2017 [cited 2019 Aug 15];
57(2):557–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2826
9765.
42. Toyn JH, Ahlijanian MK. Interpreting Alzheimer’s disease clinical trials in light
of the effects on amyloid-β. Alzheimer’s Research & Therapy. 2014;6(2):14.
Available from: https://doi.org/10.1186/alzrt244.
43. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al.
Tau positron emission tomographic imaging in aging and early Alzheimer
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 11 of 17
disease. Annals of Neurology. 2016;79(1):110–9. Available from: https://doi.
org/10.1002/ana.24546.
44. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple
isoforms of human microtubule-associated protein tau: sequences and
localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989
[cited 2019 Aug 15];3(4):519–26. Available from: https://www.sciencedirect.
com/science/article/pii/0896627389902109?via%3Dihub.
45. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein
isoforms, phosphorylation and role in neurodegenerative disorders. Brain
research Brain research reviews. 2000 [cited 2019 Aug 15];33(1):95–130.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/10967355.
46. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna
LG, et al. Validating novel tau positron emission tomography tracer [F-18]-
AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015 1;78(5):787–
800. Available from: https://doi.org/10.1002/ana.24517.
47. Marquié M, Normandin MD, Meltzer AC, Siao Tick Chong M, Andrea N v,
Antón-Fernández A, et al. Pathological correlations of [F-18]-AV-1451
imaging in non-alzheimer tauopathies. Annals of Neurology. 2017;81(1):117–
28. Available from: https://doi.org/10.1002/ana.24844.
48. Lowe VJ, Lundt ES, Albertson SM, Min H-K, Fang P, Przybelski SA, et al. Tau-
positron emission tomography correlates with neuropathology findings.
Alzheimer’sDementia. 2019; Available from: http://www.sciencedirect.com/
science/article/pii/S1552526019354755.
49. Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, et al.
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology
in MAPT mutation carriers. Brain. 2016;139(9):2372–9. Available from: https://
doi.org/10.1093/brain/aww163.
50. Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo
[18F]Flortaucipir with postmortem Alzheimer disease tau pathology. JAMA
Neurology. 2019;76(3):310–7. Available from: https://doi.org/10.1001/
jamaneurol.2018.3692.
51. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M,
et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of
Tau pathology in Alzheimer disease. J Nucl Med. 2013;54(8):1420–7.
52. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging
of tau pathology in a tauopathy mouse model and in Alzheimer patients
compared to normal controls. Neuron. 2013 [cited 2019 Aug 15];79(6):1094–
108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24050400.
53. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early
clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.
J Alzheimer’s Dis. 2013 [cited 2019 Aug 15];34(2):457–68. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23234879.
54. Gobbi LC, Knust H, Körner M, Honer M, Czech C, Belli S, et al. Identification
of three novel radiotracers for imaging aggregated tau in Alzheimer’s
disease with positron emission tomography. J Medicinal Chem. 2017 ;60(17):
7350–70. Available from: https://doi.org/10.1021/acs.jmedchem.7b00632.
55. Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, et al.
Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-
amine ([(18)F]-MK-6240): a positron emission tomography (PET) imaging
agent for quantification of neurofibrillary tangles (NFTs). Journal of
medicinal chemistry. 2016 [cited 2019 Aug 15];59(10):4778–89. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/27088900.
56. Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam
R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240
on human postmortem brain tissue. Acta Neuropathologica
Communications. 2019;7(1):37. Available from: https://doi.org/10.1186/
s40478-019-0686-6.
57. Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The
development and validation of tau PET tracers: current status and
future directions. Clinical and Translational Imaging. 2018/07/20. 2018;
6(4):305–16. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3
0148121.
58. Sanabria Bohórquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O,
et al. [18F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting
neurofibrillary tangle tau pathology in Alzheimer’s disease. European journal
of Nuclear Medicine and Molecular Imaging. 2019;46(10):2077–89. Available
from: https://doi.org/10.1007/s00259-019-04399-0.
59. Fawaz M v, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ,
et al. High affinity radiopharmaceuticals based upon lansoprazole for PET
imaging of aggregated tau in Alzheimer’s disease and progressive
supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS
chemical neuroscience. 2014/06/16. 2014;5(8):718–30. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/24896980.
60. Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, et al.
Discovery of 6-(Fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-
amine ([18F]-MK-6240): a positron emission tomography (PET) imaging
agent for quantification of neurofibrillary tangles (NFTs). Journal of
Medicinal Chemistry. 2016;59(10):4778–89. Available from: https://doi.org/10.
1021/acs.jmedchem.6b00166.
61. Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al.
Preclinical characterization of 18F-MK-6240, a promising PET tracer for
in vivo quantification of human neurofibrillary tangles. Journal of Nuclear
Medicine. 2016;57(10):1599–606 Available from: http://jnm.snmjournals.org/
content/57/10/1599.abstract.
62. Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S,
et al. First in-human PET study of 3 novel tau radiopharmaceuticals:
[11C]RO6924963, [11C]RO6931643, and [18F]RO6958948. Journal of Nuclear
Medicine. 2018; Available from: http://jnm.snmjournals.org/content/early/2
018/05/03/jnumed.118.209916.abstract.
63. Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R,
et al. PET imaging of tau deposition in the aging human brain. Neuron.
2016 [cited 2019 Aug 15];89(5):971–82. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/26938442.
64. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathologica. 1991;82(4):239–59. Available from: https://doi.org/10.
1007/BF00308809.
65. Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical
spreading pattern of tau and amyloid in the Alzheimer disease spectrum.
Annals of neurology. 2016 [cited 2019 Aug 15];80(2):247–58. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27323247.
66. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N,
Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical
variability in Alzheimer’s disease. Brain. 2016 [cited 2019 Aug 15];
139(Pt 5):1551–67. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/26962052.
67. Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al.
Association of in vivo [18F]AV-1451 tau PET imaging results with cortical
atrophy and symptoms in typical and atypical Alzheimer disease. JAMA
neurology. 2017 [cited 2019 Aug 15];74(4):427–36. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/28241163.
68. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I,
et al. Primary age-related tauopathy (PART): a common pathology
associated with human aging. Acta neuropathologica. 2014 [cited 2019 Aug
15];128(6):755–66. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/25348064.
69. Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS,
Machulda MM, et al. Tau aggregation influences cognition and
hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-
pathological study of primary age-related tauopathy (PART). Acta
neuropathologica. 2017 [cited 2019 Aug 15];133(5):705–15. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28160067.
70. Adams JN, Lockhart SN, Li L, Jagust WJ. Relationships between tau and
glucose metabolism reflect Alzheimer’s disease pathology in cognitively
normal older adults. Cerebral cortex (New York, NY : 1991). 2019 [cited 2019
Aug 15];29(5):1997–2009. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/29912295.
71. Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al.
Entorhinal tau pathology, episodic memory decline, and neurodegeneration
in aging. J Neurosci. 2018 [cited 2019 Aug 15];38(3):530–43. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/29192126.
72. Hanseeuw BJ, Betensky RA, Schultz AP, Papp K v, Mormino EC, Sepulcre J,
et al. Fluorodeoxyglucose metabolism associated with tau-amyloid
interaction predicts memory decline. Annals Neurol. 2017 [cited 2019 Aug
15];81(4):583–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2
8253546.
73. Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS,
et al. Associations between tau, Aβ, and cortical thickness with cognition in
Alzheimer disease. Neurology. 2019;92(6):e601. Available from: http://n.
neurology.org/content/92/6/e601.abstract.
74. Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A
multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild
cognitive impairment and Alzheimer’s disease dementia. Brain. 2019 [cited
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 12 of 17
2019 Aug 15];142(6):1723–35. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/31009046.
75. Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O,
et al. Discriminative accuracy of [18F]flortaucipir positron emission
tomography for Alzheimer disease vs other neurodegenerative disorders.
JAMA. 2018 [cited 2019 Aug 15];320(11):1151–62. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/30326496.
76. Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel PS, et al.
Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of
Alzheimer disease. Neurology. 2018/01/10. 2018;90(5):e388–95. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/29321235.
77. Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, et al.
Evaluation of tau imaging in staging Alzheimer disease and revealing
interactions between β-amyloid and tauopathy. JAMA neurology. 2016
[cited 2019 Aug 15];73(9):1070–7. Available from: http://www.ncbi.nlm.nih.
gov/pubmed/27454922.
78. Pontecorvo MJ, Devous Sr MD, Navitsky M, Lu M, Salloway S, Schaerf FW,
et al. Relationships between flortaucipir PET tau binding and amyloid
burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748–63.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/28077397.
79. Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and
amyloid-β proteinopathies in Alzheimer disease and other conditions.
Nature reviews Neurology. 2018 [cited 2019 Aug 15];14(4):225–36. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/29449700.
80. Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE,
et al. Structural tract alterations predict downstream tau accumulation
in amyloid-positive older individuals. Nature Neuroscience. 2018/02/05.
2018;21(3):424–31. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/29403032.
81. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive
disease. Nature. 2008;455:903. Available from: https://doi.org/10.1038/
nature07456.
82. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al.
Physical basis of cognitive alterations in Alzheimer’s disease: synapse
loss is the major correlate of cognitive impairment. Ann Neurol. 1991
[cited 2019 Aug 15];30(4):572–80. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/1789684.
83. Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VM-Y, et al.
Perforant path synaptic loss correlates with cognitive impairment and
Alzheimer’s disease in the oldest-old. Brain. 2014/07/09. 2014;137(Pt 9):
2578–87. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25012223.
84. Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin S, Chen M-K, et al.
Imaging synaptic density in the living human brain. Sci Transl Med.
2016;8(348):348ra96. Available from: http://stm.sciencemag.org/content/
8/348/348ra96.abstract.
85. Rabiner EA. Imaging synaptic density: a different look at neurologic
diseases. J Nuclear Med. 2018;59(3):380–1 Available from: http://jnm.
snmjournals.org/content/59/3/380.short.
86. Vogl C, Tanifuji S, Danis B, Daniels V, Foerch P, Wolff C, et al. Synaptic vesicle
glycoprotein 2A modulates vesicular release and calcium channel function
at peripheral sympathetic synapses. Eur J Neurosci. 2015;41(4):398–409.
Available from: https://doi.org/10.1111/ejn.12799.
87. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH.
Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J
Neurosci. 1994;14(9):5223. Available from: http://www.jneurosci.org/
content/14/9/5223.abstract.
88. Nabulsi NB, Mercier J, Holden D, Carré S, Najafzadeh S, Vandergeten M-C,
et al. Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for
imaging the synaptic vesicle glycoprotein 2A in the brain. J Nuclear
Medicine. 2016;57(5):777–84 Available from: http://jnm.snmjournals.org/
content/57/5/777.abstract.
89. Finnema SJ, Nabulsi NB, Mercier J, Lin S-F, Chen M-K, Matuskey D, et al.
Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel
radioligand for positron emission tomography imaging of synaptic vesicle
glycoprotein 2A in humans. Journal of cerebral blood flow and metabolism
: official journal of the International Society of Cerebral Blood Flow and
Metabolism. 2018 [cited 2019 Aug 15];38(11):2041–52. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/28792356.
90. Zheng M-Q, Holden D, Nabulsi N, Lin S, Mercier J, Hannestad J, et al.
Synthesis and evaluation of 18F-UCB-H, a novel PET imaging tracer for
the synaptic vesicle protein 2A. J Nuclear Medicine. 2014;55(supplement
1):1792. Available from: http://jnm.snmjournals.org/content/55/
supplement_1/1792.abstract.
91. Bretin F, Bahri MA, Bernard C, Warnock G, Aerts J, Mestdagh N, et al.
Biodistribution and radiation dosimetry for the novel SV2A radiotracer
[18F]UCB-H: first-in-human study. Molecular Imaging Biol. 2015;17(4):557–64.
Available from: https://doi.org/10.1007/s11307-014-0820-6.
92. Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In
vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H
positron emission tomography. Eur J Nuclear Med Molecular Imaging. 2020;
47(2):390–402. Available from: https://doi.org/10.1007/s00259-019-04461-x.
93. Iaccarino L, Sala A, Caminiti SP, Perani D. The emerging role of PET imaging
in dementia. F1000Research. 2017;6:1830. Available from: https://www.ncbi.
nlm.nih.gov/pubmed/29071066.
94. Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al.
SNMMI procedure standard/EANM practice guideline for amyloid PET
imaging of the brain 1.0. Journal of Nuclear Medicine. 2016;57(8):1316–22.
Available from: http://jnm.snmjournals.org/content/57/8/1316.short.
95. Suppiah S, Didier M-A, Vinjamuri S. The who, when, why, and how of PET
amyloid imaging in management of Alzheimer’s disease-review of literature
and interesting images. Diagnostics (Basel, Switzerland). 2019;9(2):65.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/31242587.
96. Wang YT, Edison P. Tau imaging in neurodegenerative diseases using
positron emission tomography. Current neurology and neuroscience
reports. 2019;19(7):45. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/31172290.
97. Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al.
Biomarkers for tau pathology. Molecular and Cellular Neuroscience. 2019;97:
18–33 Available from: http://www.sciencedirect.com/science/article/pii/S1
044743118302331.
98. Leuzy A, Chiotis K, Lemoine L, Gillberg P-G, Almkvist O, Rodriguez-Vieitez E,
et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge.
Molecular psychiatry. 2019;24(8):1112–34. Available from: https://doi.org/10.
1038/s41380-018-0342-8.
99. Klunk WE. Molecular imaging: what is right and what is an illusion?
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2018;
10:217–20 Available from: http://www.sciencedirect.com/science/article/pii/
S2352872918300046.
100. Rossano S, Toyonaga T, Finnema SJ, Naganawa M, Lu Y, Nabulsi N, et al.
Assessment of a white matter reference region for 11C-UCB-J PET
quantification. Journal of Cerebral Blood Flow & Metabolism. 2019;
0271678X19879230. Available from: https://doi.org/10.1177/
0271678X19879230.
101. (No Title). Dementia: assessment, management and support for people
living with dementia and their carers. 2018 [Cited 2019 Aug 21]. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/30011160.
102. Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, et al. The
topography of grey matter involvement in early and late onset Alzheimer’s
disease. Brain. 2007;130(3):720–30. Available from: https://doi.org/10.1093/
brain/awl377.
103. Möller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, et al.
Different patterns of gray matter atrophy in early- and late-onset
Alzheimer’s disease. Neurobiology of Aging. 2013 [cited 2019 Aug 21];34(8):
2014–22. Available from: https://www.sciencedirect.com/science/article/pii/
S0197458013000869?via%3Dihub.
104. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD,
et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-
based morphometry study. Neurology. 2008;71(10):743–9. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/18765650.
105. Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al.
Presymptomatic cognitive and neuroanatomical changes in genetic
frontotemporal dementia in the Genetic Frontotemporal dementia Initiative
(GENFI) study: a cross-sectional analysis. The Lancet Neurology. 2015 [cited
2019 Aug 21];14(3):253–62. Available from: https://www.sciencedirect.com/
science/article/pii/S1474442214703242?via%3Dihub.
106. Mahoney CJ, Downey LE, Ridgway GR, Beck J, Clegg S, Blair M, et al.
Longitudinal neuroimaging and neuropsychological profiles of
frontotemporal dementia with C9ORF72 expansions. Alzheimer’s research &
therapy. 2012;4(5):41. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/23006986.
107. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH,
et al. Vascular dementia: diagnostic criteria for research studies. Report of
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 13 of 17
the NINDS-AIREN International Workshop. Neurology. 1993 [cited 2019
Aug 22];43(2):250–60. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/8094895.
108. Haller S, Vernooij MW, Kuijer JPA, Larsson E-M, Jäger HR, Barkhof F. Cerebral
microbleeds: imaging and clinical significance. Radiology. 2018;287(1):11–28.
Available from: https://doi.org/10.1148/radiol.2018170803.
109. Kallenberg K, Schulz-Schaeffer WJ, Jastrow U, Poser S, Meissner B, Tschampa
HJ, et al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging
sequences. Am J Neuroradiology. 2006;27(7):1459. Available from: http://
www.ajnr.org/content/27/7/1459.abstract.
110. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH,
et al. The diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimer’s & Dementia 2011/04/21. 2011;7(3):263–9. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/21514250.
111. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier
WM, et al. Consensus classification of posterior cortical atrophy. Alzheimer’s
& Dementia. 2017/03/02. 2017;13(8):870–84. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/28259709.
112. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF,
et al. Classification of primary progressive aphasia and its variants.
Neurology. 2011/02/16. 2011;76(11):1006–14. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/21325651.
113. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al.
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal
dementia. Brain : a journal of neurology. 2011/08/02. 2011 Sep;134(Pt 9):2456–77.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/21810890.
114. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al.
Diagnosis and management of dementia with Lewy bodies: fourth
consensus report of the DLB Consortium. Neurology. 2017/06/07. 2017;89(1):
88–100. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28592453.
115. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al.
Second consensus statement on the diagnosis of multiple system atrophy.
Neurology. 2008;71(9):670–6. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/18725592.
116. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE,
et al. Clinical diagnosis of progressive supranuclear palsy: the movement
disorder society criteria. Movement disorders : official journal of the
Movement Disorder Society. 2017/05/03. 2017 Jun;32(6):853–64. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/28467028.
117. Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O’Brien JT, et al.
Patterns of atrophy in pathologically confirmed dementias: a voxelwise
analysis. Journal of Neurology, Neurosurgery &amp;amp; Psychiatry. 2017;
88(11):908. Available from: http://jnnp.bmj.com/content/88/11/908.abstract.
118. Jack Jr CR, Dickson DW, Parisi JE, Xu YC, Cha RH, O’Brien PC, et al.
Antemortem MRI findings correlate with hippocampal neuropathology in
typical aging and dementia. Neurology. 2002;58(5):750–7. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/11889239.
119. Boon BDC, Pouwels PJW, Jonkman LE, Keijzer MJ, Preziosa P, van de Berg
WDJ, et al. Can post-mortem MRI be used as a proxy for in vivo? A case
study. Brain Communications. 2019;1(1). Available from: https://doi.org/10.
1093/braincomms/fcz030.
120. Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS,
et al. Tracking pathophysiological processes in Alzheimer’s disease: an
updated hypothetical model of dynamic biomarkers. The Lancet Neurology.
2013;12(2):207–16. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/23332364.
121. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al.
Tracking atrophy progression in familial Alzheimer’s disease: a serial MRI
study. The Lancet Neurology. 2006 [cited 2019 Aug 21];5(10):828–34.
Available from: https://www.sciencedirect.com/science/article/pii/S14744422
06705506?via%3Dihub.
122. Hill DLG, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, et al.
Coalition Against Major Diseases/European Medicines Agency biomarker
qualification of hippocampal volume for enrichment of clinical trials in
predementia stages of Alzheimer’s disease. Alzheimer’s & Dementia. 2014
Jul 1 [cited 2019 Aug 21];10(4):421–429.e3. Available from: https://www.
sciencedirect.com/science/article/pii/S1552526013024977?via%3Dihub.
123. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered
brain magnetic resonance imaging to measure disease progression in
Alzheimer disease: power calculations and estimates of sample size to
detect treatment effects. JAMA Neurology. 2000;57(3):339–44. Available
from: https://doi.org/10.1001/archneur.57.3.339.
124. Kulason S, Tward DJ, Brown T, Sicat CS, Liu C-F, Ratnanather JT, et al.
Cortical thickness atrophy in the transentorhinal cortex in mild cognitive
impairment. NeuroImage Clinical. 2018/12/05. 2019;21:101617. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/30552075.
125. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The
cortical signature of Alzheimer’s disease: regionally specific cortical thinning
relates to symptom severity in very mild to mild AD dementia and is
detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex.
2008;19(3):497–510. Available from: https://doi.org/10.1093/cercor/bhn113.
126. Kälin AM, Park MTM, Chakravarty MM, Lerch JP, Michels L, Schroeder C,
et al. Subcortical shape changes, hippocampal atrophy and cortical
thinning in future Alzheimer’s disease patients. Frontiers in Aging
Neuroscience. 2017;9:38. Available from: https://www.frontiersin.org/
article/10.3389/fnagi.2017.00038.
127. Du A-T, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, et al.
Different regional patterns of cortical thinning in Alzheimer’s disease and
frontotemporal dementia. Brain. 2007;130(4):1159–66. Available from:
https://doi.org/10.1093/brain/awm016.
128. Lindberg O, Walterfang M, Looi JCL, Malykhin N, Ostberg P, Zandbelt B,
et al. Hippocampal shape analysis in Alzheimer’s disease and
frontotemporal lobar degeneration subtypes. Journal of Alzheimer’s disease
: JAD. 2012;30(2):355–65. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/22414571.
129. Wang J, Ekin A, Haan G de. Shape analysis of brain ventricles for improved
classification of Alzheimer’s patients. In: 2008 15th IEEE International
Conference on Image Processing. 2008. p. 2252–5.
130. Berron D, Vieweg P, Hochkeppler A, Pluta JB, Ding S-L, Maass A, et al. A
protocol for manual segmentation of medial temporal lobe subregions in 7
Tesla MRI. NeuroImage Clinical. 2017;15:466–82. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/28652965.
131. Wisse LEM, Gerritsen L, Zwanenburg JJM, Kuijf HJ, Luijten PR, Biessels GJ,
et al. Subfields of the hippocampal formation at 7 T MRI: in vivo volumetric
assessment. NeuroImage. 2012 [cited 2019 Aug 21];61(4):1043–9. Available
from: https://www.sciencedirect.com/science/article/pii/S105381191200296
0?via%3Dihub.
132. Evans TE, Adams HHH, Licher S, Wolters FJ, van der Lugt A, Ikram MK, et al.
Subregional volumes of the hippocampus in relation to cognitive function
and risk of dementia. NeuroImage. 2018 [cited 2019 Sep 5];178:129–35.
Available from: https://www.sciencedirect.com/science/article/pii/S1053811
918304488?via%3Dihub.
133. Carlesimo GA, Piras F, Orfei MD, Iorio M, Caltagirone C, Spalletta G. Atrophy
of presubiculum and subiculum is the earliest hippocampal anatomical
marker of Alzheimer’s disease. Alzheimer’s & dementia (Amsterdam,
Netherlands). 2015;1(1):24–32. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/27239489.
134. Wolk DA, Das SR, Mueller SG, Weiner MW, Yushkevich PA, Initiative ADN.
Medial temporal lobe subregional morphometry using high resolution MRI
in Alzheimer’s disease. Neurobiology of aging. 2016/09/30. 2017; 49:204–13.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27836336.
135. Betts MJ, Acosta-Cabronero J, Cardenas-Blanco A, Nestor PJ, Düzel E. High-
resolution characterisation of the aging brain using simultaneous
quantitative susceptibility mapping (QSM) and R2* measurements at 7 T.
NeuroImage. 2016 [cited 2019 Aug 21];138:43–63. Available from: https://
www.sciencedirect.com/science/article/pii/S1053811916301446?via%3Dihub.
136. Daugherty AM, Haacke EM, Raz N. Striatal iron content predicts its shrinkage
and changes in verbal working memory after two years in healthy adults. J
Neurosc. 2015;35(17):6731–43. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/25926451.
137. Ghadery C, Pirpamer L, Hofer E, Langkammer C, Petrovic K, Loitfelder M,
et al. R2* mapping for brain iron: associations with cognition in normal
aging. Neurobiol Aging. 2015 [cited 2019 Aug 21];36(2):925–32. Available
from: https://www.sciencedirect.com/science/article/pii/S0197458014006186
?via%3Dihub.
138. Sullivan E v, Adalsteinsson E, Rohlfing T, Pfefferbaum A. Relevance of iron
deposition in deep gray matter brain structures to cognitive and motor
performance in healthy elderly men and women: exploratory findings. Brain
Imaging Behavior. 2009 ;3(2):167–75. Available from: https://www.ncbi.nlm.
nih.gov/pubmed/20161183.
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 14 of 17
139. Li W, Langkammer C, Chou Y-H, Petrovic K, Schmidt R, Song AW, et al.
Association between increased magnetic susceptibility of deep gray matter
nuclei and decreased motor function in healthy adults. NeuroImage. 2014/
10/12. 2015;105:45–52. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/25315786.
140. Acosta-Cabronero J, Williams GB, Cardenas-Blanco A, Arnold RJ, Lupson V,
Nestor PJ. In vivo quantitative susceptibility mapping (QSM) in Alzheimer’s
disease. PloS One. 2013 ;8(11):e81093–e81093. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/24278382.
141. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW,
et al. In vivo evaluation of brain iron in Alzheimer disease using
magnetic resonance imaging. Archives General Psychiatry. 2000 [cited
2019 Aug 22];57(1):47–53. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/10632232.
142. Möller HE, Bossoni L, Connor JR, Crichton RR, Does MD, Ward RJ, et al. Iron,
myelin, and the brain: neuroimaging meets neurobiology. Vol. 42, Trends in
Neurosciences. Elsevier Ltd; 2019. p. 384–401.
143. Bagnato F, Hametner S, Welch EB. Visualizing iron in multiple sclerosis.
Magnetic resonance imaging. 2013/01/22. 2013;31(3):376–84. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/23347601.
144. Wisnieff C, Ramanan S, Olesik J, Gauthier S, Wang Y, Pitt D. Quantitative
susceptibility mapping (QSM) of white matter multiple sclerosis lesions:
interpreting positive susceptibility and the presence of iron. Magnetic
Resonance Med. 2014/08/18. 2015;74(2):564–70. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/25137340.
145. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain
ageing and neurodegenerative disorders. Lancet Neurol 2014 ;13(10):1045–
60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25231526.
146. Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, Butryn M, Valdes-Herrera
JP, Galazky I, et al. The whole-brain pattern of magnetic susceptibility
perturbations in Parkinson’s disease. Brain. 2016;140(1):118–31. Available
from: https://doi.org/10.1093/brain/aww278.
147. Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, et al. Cerebral
quantitative susceptibility mapping predicts amyloid-β-related cognitive
decline. Brain. 2017;140(8):2112–9. Available from: https://doi.org/10.1093/
brain/awx137.
148. Hohenfeld C, Werner CJ, Reetz K. Resting-state connectivity in
neurodegenerative disorders: is there potential for an imaging biomarker?
NeuroImage: Clinical. 2018 [cited 2019 Aug 15];18:849–70. Available from:
https://www.sciencedirect.com/science/article/pii/S2213158218300834.
149. Bayram E, Caldwell JZK, Banks SJ. Current understanding of magnetic
resonance imaging biomarkers and memory in Alzheimer’s disease.
Alzheimer’s Dementia. 2018 [cited 2019 Aug 15];4:395–413. Available from:
https://www.sciencedirect.com/science/article/pii/S2352873718300258.
150. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity
distinguishes Alzheimer’s disease from healthy aging: evidence from
functional MRI. Proc National Acad Sci U. S. A. 2004;101(13):4637. Available
from: http://www.pnas.org/content/101/13/4637.abstract.
151. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, et al. Medial
temporal lobe function and structure in mild cognitive impairment. Ann
Neurol. 2004;56(1):27–35. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/15236399.
152. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative
diseases target large-scale human brain networks. Neuron. 2009;62(1):42–52.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/19376066.
153. Sperling RA, Laviolette PS, O’Keefe K, O’Brien J, Rentz DM, Pihlajamaki M,
et al. Amyloid deposition is associated with impaired default network
function in older persons without dementia. Neuron. 2009;63(2):178–88.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/19640477.
154. Vannini P, Hedden T, Becker JA, Sullivan C, Putcha D, Rentz D, et al. Age and
amyloid-related alterations in default network habituation to stimulus
repetition. Neurobiol Aging. 2011/02/18. 2012 ;33(7):1237–52. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/21334099.
155. Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M. Response of the
medial temporal lobe network in amnestic mild cognitive impairment to
therapeutic intervention assessed by fMRI and memory task performance.
NeuroImage: Clinical. 2015 [cited 2019 Aug 15];7:688–98. Available from:
https://www.sciencedirect.com/science/article/pii/S2213158215000273.
156. Leal SL, Landau SM, Bell RK, Jagust WJ. Hippocampal activation is associated
with longitudinal amyloid accumulation and cognitive decline. eLife. 2017;6:
e22978. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28177283.
157. Huijbers W, Schultz AP, Papp K V, LaPoint MR, Hanseeuw B, Chhatwal JP,
et al. Tau accumulation in clinically normal older adults is associated with
hippocampal hyperactivity. J Neurosci. 2018/11/27. 201939(3):548–56.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/30482786.
158. Maass A, Berron D, Harrison TM, Adams JN, la Joie R, Baker S, et al.
Alzheimer’s pathology targets distinct memory networks in the ageing
brain. Brain. 2019;142(8):2492–509. Available from: https://doi.org/10.1093/
brain/awz154.
159. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA,
Mazziotta JC, et al. Patterns of brain activation in people at risk for
Alzheimer’s disease. New England J Med 2000;343(7):450–6. Available from:
https://doi.org/10.1056/NEJM200008173430701.
160. Foster CM, Kennedy KM, Horn MM, Hoagey DA, Rodrigue KM. Both hyper-
and hypo-activation to cognitive challenge are associated with increased
beta-amyloid deposition in healthy aging: a nonlinear effect. NeuroImage.
2018 [cited 2019 Aug 15];166:285–92. Available from: https://www.
sciencedirect.com/science/article/pii/S1053811917309060.
161. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al.
Alterations in memory networks in mild cognitive impairment and
Alzheimer’s disease: an independent component analysis. J Neurosci.
2006;26(40):10222. Available from: http://www.jneurosci.org/content/26/4
0/10222.abstract.
162. Haller S, Zaharchuk G, Thomas DL, Lovblad K-O, Barkhof F, Golay X. Arterial
spin labeling perfusion of the brain: emerging clinical applications.
Radiology. 2016;281(2):337–56. Available from: https://doi.org/10.1148/radiol.
2016150789.
163. Petcharunpaisan S, Ramalho J, Castillo M. Arterial spin labeling in
neuroimaging. World J Radiol. 2010;2(10):384–98. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/21161024.
164. Anazodo UC, Finger E, Kwan BYM, Pavlosky W, Warrington JC, Günther M,
et al. Using simultaneous PET/MRI to compare the accuracy of diagnosing
frontotemporal dementia by arterial spin labelling MRI and FDG-PET.
NeuroImage: Clinical. 2018;17:405–14 Available from: http://www.
sciencedirect.com/science/article/pii/S2213158217302747.
165. Du AT, Jahng GH, Hayasaka S, Kramer JH, Rosen HJ, Gorno-Tempini ML,
et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by
arterial spin labeling MRI. Neurology. 2006;67(7):1215–20 Available from:
https://www.ncbi.nlm.nih.gov/pubmed/17030755.
166. Wandell BA. Clarifying human white matter. Annual Review Neurosci. 2016
;39(1):103–28. Available from: https://doi.org/10.1146/annurev-neuro-070815-
013815.
167. Filley CM, Fields RD. White matter and cognition: making the connection. J
Neurophysiol. 2016/08/10. 2016;116(5):2093–104. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/27512019.
168. Soares JM, Marques P, Alves V, Sousa N. A hitchhiker’s guide to diffusion
tensor imaging. Front Neurosci 2013;7:31. Available from: https://www.ncbi.
nlm.nih.gov/pubmed/23486659.
169. Acosta-Cabronero J, Nestor PJ. Diffusion tensor imaging in Alzheimer’s
disease: insights into the limbic-diencephalic network and methodological
considerations. Front Aging Neurosci. 2014;6:266. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/25324775.
170. Teipel S, Drzezga A, Grothe MJ, Barthel H, Chételat G, Schuff N, et al.
Multimodal imaging in Alzheimer’s disease: validity and usefulness for early
detection. Lancet Neurol 2015 [cited 2019 Aug 16];14(10):1037–53. Available
from: https://www.sciencedirect.com/science/article/pii/S147444221500093
9?via%3Dihub.
171. Mayo CD, Garcia-Barrera MA, Mazerolle EL, Ritchie LJ, Fisk JD, Gawryluk JR,
et al. Relationship between DTI metrics and cognitive function in
Alzheimer’s disease. Front Aging neuroscience. 2019;10:436. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/30687081.
172. Song Z, Farrell ME, Chen X, Park DC. Longitudinal accrual of neocortical
amyloid burden is associated with microstructural changes of the fornix in
cognitively normal adults. Neurobiol Aging. 2018/03/06. 2018;68:114–22.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/29602495.
173. Tang M, Chen X, Zhou Q, Liu B, Liu Y, Liu S, et al. Quantitative assessment
of amyotrophic lateral sclerosis with diffusion tensor imaging in 3.0T
magnetic resonance. International journal of clinical and experimental
medicine. 2015;8(5):8295–303. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/26221413.
174. Jones DK, Knösche TR, Turner R. White matter integrity, fiber count, and
other fallacies: the do’s and don’ts of diffusion MRI. NeuroImage. 2013 [cited
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 15 of 17
2019 Aug 16];73:239–54. Available from: https://www.sciencedirect.com/
science/article/pii/S1053811912007306?via%3Dihub.
175. Mulders PC, van Eijndhoven PF, Beckmann CF. Identifying large-scale neural
networks using fMRI. Systems Neuroscience in Depression. 2016 [cited 2019
Aug 16];209–37. Available from: https://www.sciencedirect.com/science/
article/pii/B9780128024560000078.
176. Dwyer DB, Harrison BJ, Yücel M, Whittle S, Zalesky A, Pantelis C, et al. Adolescent
cognitive control: brain network dynamics. Stress: Concepts, Cognition, Emotion,
and Behavior. 2016 [cited 2019 Aug 16];177–85. Available from: https://www.
sciencedirect.com/science/article/pii/B9780128009512000212.
177. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of
structural and functional systems. Nature Reviews Neurosci. 2009;10:186.
Available from: https://doi.org/10.1038/nrn2575.
178. Fornito A, Bullmore ET. Connectomics: a new paradigm for understanding
brain disease. European Neuropsychopharmacology. 2015 [cited 2019 Aug
16];25(5):733–48. Available from: https://www.sciencedirect.com/science/
article/pii/S0924977X14000807?via%3Dihub.
179. Pereira JB, van Westen D, Stomrud E, Strandberg O, Volpe G, Westman E,
et al. Abnormal structural brain connectome in individuals with preclinical
Alzheimer’s disease. Alzheimer’s Dementia. 2017 [cited 2019 Aug 16];13(7):
P7. Available from: https://www.sciencedirect.com/science/article/pii/
S1552526017328832.
180. Çiftçi K. Minimum spanning tree reflects the alterations of the default mode
network during Alzheimer’s disease. Ann Biomed Engi 2011;39(5):1493–504
Available from: https://doi.org/10.1007/s10439-011-0258-9.
181. Pereira JB, Strandberg TO, Palmqvist S, Volpe G, van Westen D, Westman E,
et al. Amyloid network topology characterizes the progression of
Alzheimer’s disease during the predementia stages. Cerebral cortex (New
York, NY : 1991). 2018;28(1):340–9. Available from: https://www.ncbi.nlm.nih.
gov/pubmed/29136123.
182. Mårtensson G, Pereira JB, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, et al.
Stability of graph theoretical measures in structural brain networks in
Alzheimer’s disease. Scientific Reports. 2018;8(1):11592 Available from:
https://doi.org/10.1038/s41598-018-29927-0.
183. Pellegrini E, Ballerini L, Hernandez MDCV, Chappell FM, González-Castro V,
Anblagan D, et al. Machine learning of neuroimaging for assisted diagnosis
of cognitive impairment and dementia: a systematic review. Alzheimer’s
Dementia (Amsterdam, Netherlands). 2018;10:519–35. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/30364671.
184. Mirzaei G, Adeli A, Adeli H. Imaging and machine learning techniques for
diagnosis of Alzheimer’s disease. Reviews in the neurosciences. 2016 [cited
2019 Aug 16];27(8):857–70. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/27518905.
185. Salvatore C, Battista P, Castiglioni I. Frontiers for the early diagnosis of AD
by means of MRI brain imaging and support vector machines. Current
Alzheimer Research. 2016 [cited 2019 Aug 16];13(5):509–33. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26567735.
186. Tohka J, Moradi E, Huttunen H, Initiative ADN. Comparison of feature
selection techniques in machine learning for anatomical brain MRI in
dementia. Neuroinformatics. 2016;14(3):279–96. Available from: https://doi.
org/10.1007/s12021-015-9292-3.
187. Dimitriadis SI, Liparas D, Initiative ADN. How random is the random forest?
Random forest algorithm on the service of structural imaging biomarkers
for Alzheimer’s disease: from Alzheimer’s disease neuroimaging initiative
(ADNI) database. Neural Regeneration Res. 2018;13(6):962–70. Available
from: https://www.ncbi.nlm.nih.gov/pubmed/29926817.
188. Lee JS, Kim C, Shin J-H, Cho H, Shin D-S, Kim N, et al. Machine learning-
based individual assessment of cortical atrophy pattern in Alzheimer’s
disease spectrum: development of the classifier and longitudinal evaluation.
Scientific Reports. 2018;8(1):4161 Available from: https://www.ncbi.nlm.nih.
gov/pubmed/29515131.
189. Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, et al.
Automated and manual hippocampal segmentation techniques:
comparison of results, reproducibility and clinical applicability. NeuroImage:
Clinical. 2019 [cited 2019 Aug 16];21:101574. Available from: https://www.
sciencedirect.com/science/article/pii/S221315821830322X.
190. Mehdipour Ghazi M, Nielsen M, Pai A, Cardoso MJ, Modat M, Ourselin S,
et al. Training recurrent neural networks robust to incomplete data:
application to Alzheimer’s disease progression modeling. Medical Image
Analysis. 2019 [cited 2019 Aug 16];53:39–46. Available from: https://www.
sciencedirect.com/science/article/abs/pii/S136184151830598X.
191. Wang Y, Xu C, Park J-H, Lee S, Stern Y, Yoo S, et al. Diagnosis and prognosis
of Alzheimer’s disease using brain morphometry and white matter
connectomes. NeuroImage: Clin. 2019 [cited 2019 Aug 16];23:101859.
Available from: https://www.sciencedirect.com/science/article/pii/S221315
8219302098?via%3Dihub.
192. Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A,
Gómez-Lado N, et al. Prediction of Alzheimer’s disease dementia with MRI
beyond the short-term: implications for the design of predictive models.
NeuroImage: Clin. 2019 [cited 2019 Aug 16];23:101837. Available from:
https://www.sciencedirect.com/science/article/pii/S2213158219301871
?via%3Dihub.
193. Bouts MJRJ, van der Grond J, Vernooij MW, Koini M, Schouten TM, de Vos F,
et al. Detection of mild cognitive impairment in a community-dwelling
population using quantitative, multiparametric MRI-based classification.
Human Brain Mapping. 2019/02/25. 2019;40(9):2711–22. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/30803110.
194. Lian C, Liu M, Zhang J, Shen D. Hierarchical fully convolutional network for
joint atrophy localization and Alzheimer’s disease diagnosis using structural
MRI. IEEE Trans Pattern Anal Mach Intell. 2018;1.
195. Li F, Liu M. Alzheimer’s disease diagnosis based on multiple cluster dense
convolutional networks. Computerized Medical Imaging and Graphics. 2018
[cited 2019 Aug 16];70:101–10. Available from: https://www.sciencedirect.
com/science/article/abs/pii/S089561111830199X.
196. Hojjati SH, Ebrahimzadeh A, Khazaee A, Babajani-Feremi A. Predicting
conversion from MCI to AD by integrating rs-fMRI and structural MRI.
Comput Biol and Medicine. 2018 [cited 2019 Aug 16];102:30–9. Available
from: https://www.sciencedirect.com/science/article/pii/S0010482518302609.
197. Ruiz E, Ramírez J, Górriz JM, Casillas J, Alzheimer’s Disease Neuroimaging
Initiative. Alzheimer’s disease computer-aided diagnosis: histogram-based
analysis of regional MRI volumes for feature selection and classification. J
Alzheimer’s Dis. 2018 [cited 2019 Aug 16];65(3):819–42. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/29966190.
198. Gómez-Sancho M, Tohka J, Gómez-Verdejo V. Comparison of feature
representations in MRI-based MCI-to-AD conversion prediction. Magnetic
Resonance Imaging. 2018 [cited 2019 Aug 16];50:84–95. Available from:
https://www.sciencedirect.com/science/article/abs/pii/S0730725X18300286
?via%3Dihub.
199. Salvatore C, Castiglioni I. A wrapped multi-label classifier for the automatic
diagnosis and prognosis of Alzheimer’s disease. J Neurosci Methods. 2018
[cited 2019 Aug 16];302:58–65. Available from: https://www.sciencedirect.
com/science/article/pii/S016502701730434X.
200. Cárdenas-Peña D, Collazos-Huertas D, Castellanos-Dominguez G. Enhanced
data representation by kernel metric learning for dementia diagnosis. Front
Neurosci. 2017;11:413. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/28798659.
201. Ardekani BA, Bermudez E, Mubeen AM, Bachman AH, Alzheimer’s Disease
Neuroimaging Initiative. Prediction of incipient Alzheimer’s disease
dementia in patients with mild cognitive impairment. J Alzheimer’s Dis.
2017 [cited 2019 Aug 16];55(1):269–81. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/27662309.
202. Wang S, Zhang Y, Liu G, Phillips P, Yuan T-F. Detection of Alzheimer’s
disease by three-dimensional displacement field estimation in structural
magnetic resonance imaging. JournalAlzheimer’s Dis. 2016 ;50(1):233–48.
[cited 2019 Aug 16] Available from: http://www.ncbi.nlm.nih.gov/
pubmed/26682696.
203. Ge C, Qu Q, Gu IY-H, Jakola AS. Multi-stream multi-scale deep convolutional
networks for Alzheimer’s disease detection using MR images.
Neurocomputing. 2019;350:60–9 [cited 2019 Aug 16] Available from: https://
www.sciencedirect.com/science/article/pii/S0925231219305478.
204. Cui R, Liu M. RNN-based longitudinal analysis for diagnosis of Alzheimer’s
disease. Comput Med Imaging Graphics. 2019;73:1–10. [cited 2019 Aug 16]
Available from: https://www.sciencedirect.com/science/article/abs/pii/
S0895611118303987.
205. Duraisamy B, Shanmugam JV, Annamalai J. Alzheimer disease detection
from structural MR images using FCM based weighted probabilistic neural
network. Brain Imaging Behavior., Available from. 2019;13(1):87–110 https://
doi.org/10.1007/s11682-018-9831-2.
206. Bi X, Li S, Xiao B, Li Y, Wang G, Ma X. Computer aided Alzheimer’s disease
diagnosis by an unsupervised deep learning technology. Neurocomputing.
2019 [cited 2019 Aug 16]; Available from: https://www.sciencedirect.com/
science/article/pii/S0925231219304709.
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 16 of 17
207. Zeng N, Qiu H, Wang Z, Liu W, Zhang H, Li Y. A new switching-delayed-
PSO-based optimized SVM algorithm for diagnosis of Alzheimer’s disease.
Neurocomputing. 2018;320:195–202 [cited 2019 Aug 16] Available from:
https://www.sciencedirect.com/science/article/pii/S0925231218310531.
208. Hosseini-Asl E, Ghazal M, Mahmoud A, Aslantas A, Shalaby AM, Casanova
MF, et al. Alzheimer’s disease diagnostics by a 3D deeply supervised
adaptable convolutional network. Front Biosci. 2018;23:584–96 [cited 2019
Aug 16] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28930562.
209. Khajehnejad M, Saatlou FH, Mohammadzade H. Alzheimer’s disease early
diagnosis using manifold-based semi-supervised learning. Brain Sci. 2017;
7(8):109 Available from: https://www.ncbi.nlm.nih.gov/pubmed/28825647.
210. Ahmed O ben, Benois-Pineau J, Allard M, Catheline G, Amar C ben.
Recognition of Alzheimer’s disease and mild cognitive impairment with
multimodal image-derived biomarkers and multiple kernel learning.
Neurocomputing. 2017 ;220:98–110. [cited 2019 Aug 16] Available from:
https://www.sciencedirect.com/science/article/pii/S0925231216308967.
211. Luo S, Li X, Li J. Automatic Alzheimer’s fisease recognition from MRI data dsing
deep learning method. J Appl Mathematics Physics. 2017;05(09):1892–8.
212. Demirhan A. Classification of structural MRI for detecting Alzheimer’s
disease. International Journal of Intelligent Systems and Applications in
Engineering. 2016 26;0(0). Available from: https://www.ijisae.org/IJISAE/
article/view/959.
213. Chen Y, Sha M, Zhao X, Ma J, Ni H, Gao W, et al. Automated detection of
pathologic white matter alterations in Alzheimer’s disease using combined
diffusivity and kurtosis method. Psychiatry Research: Neuroimaging. 2017;
264:35–45 [cited 2019 Aug 16] Available from: https://www.sciencedirect.
com/science/article/pii/S092549271630186X.
214. Basaia S, Agosta F, Wagner L, Canu E, Magnani G, Santangelo R, et al.
Automated classification of Alzheimer’s disease and mild cognitive
impairment using a single MRI and deep neural networks. NeuroImage Clin.
2018/12/18. 2019;21:101645. Available from: https://www.ncbi.nlm.nih.gov/
pubmed/30584016.
215. Liu M, Cheng D, Wang K, Wang Y, Initiative the ADN. Multi-modality
cascaded convolutional neural networks for Alzheimer’s disease diagnosis.
Neuroinformatics, Available from. 2018;16(3):295–308 https://doi.org/10.
1007/s12021-018-9370-4.
216. Zhang Y, Liu S. Analysis of structural brain MRI and multi-parameter
classification for Alzheimer’s disease. Biomedizinische Technik Biomed Eng.
2018;63(4):427–37 [cited 2019 Aug 16] Available from: http://www.ncbi.nlm.
nih.gov/pubmed/28622141.
217. Spasov S, Passamonti L, Duggento A, Liò P, Toschi N. A parameter-efficient
deep learning approach to predict conversion from mild cognitive
impairment to Alzheimer’s disease. NeuroImage. 2019;189:276–87 [cited
2019 Aug 16] Available from: https://www.sciencedirect.com/science/article/
pii/S105381191930031X.
218. Sun Z, Qiao Y, Lelieveldt BPF, Staring M. Integrating spatial-anatomical
regularization and structure sparsity into SVM: Improving interpretation of
Alzheimer’s disease classification. NeuroImage. 2018;178:445–60 [cited 2019
Aug 16] Available from: https://www.sciencedirect.com/science/article/pii/S1
053811918304658.
219. Kim JP, Kim J, Park YH, Park SB, Lee JS, Yoo S, et al. Machine learning based
hierarchical classification of frontotemporal dementia and Alzheimer’s
disease. NeuroImage Clin. 2019;23:101811 Available from: https://www.ncbi.
nlm.nih.gov/pubmed/30981204.
220. Neffati S, ben Abdellafou K, Jaffel I, Taouali O, Bouzrara K. An improved
machine learning technique based on downsized KPCA for Alzheimer’s
disease classification. Int J Imaging Syst Technol. 2019;29(2):121–31.
Available from: https://doi.org/10.1002/ima.22304.
221. Singh G, Samavedham L, Lim EC-H. Determination of imaging biomarkers
to decipher disease trajectories and differential diagnosis of
neurodegenerative diseases (DIsease TreND). J Neurosci Methods. 2018;305:
105–16 [cited 2019 Aug 16] Available from: https://www.sciencedirect.com/
science/article/pii/S0165027018301407?via%3Dihub.
222. Asim Y, Raza B, Malik AK, Rathore S, Hussain L, Iftikhar MA. A multi-modal,
multi-atlas-based approach for Alzheimer detection via machine learning.
Int J Imaging Syst Technol. 2018 1;28(2):113–23. Available from: https://doi.
org/10.1002/ima.22263.
223. Lu D, Popuri K, Ding GW, Balachandar R, Beg MF, Initiative ADN. Multimodal
and multiscale deep neural networks for the early diagnosis of Alzheimer’s
disease using structural MR and FDG-PET images. Scientific Reports. 2018;
8(1):5697 Available from: https://www.ncbi.nlm.nih.gov/pubmed/29632364.
224. Yan Y, Somer E, Grau V. Classification of amyloid PET images using novel
features for early diagnosis of Alzheimer’s disease and mild cognitive
impairment conversion. Nuclear Med Commun. 2019;40(3):242–8 [cited 2019
Aug 16] Available from: http://www.ncbi.nlm.nih.gov/pubmed/30507747.
225. An L, Adeli E, Liu M, Zhang J, Lee S-W, Shen D. A hierarchical feature and
sample selection framework and its application for Alzheimer’s disease
diagnosis. Scientific Reports. 2017;7:45269 Available from: https://doi.org/10.
1038/srep45269.
226. Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al.
Neuronal network disintegration: common pathways linking
neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2016;87(11):1234
Available from: http://jnnp.bmj.com/content/87/11/1234.abstract.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Young et al. Alzheimer's Research & Therapy           (2020) 12:49 Page 17 of 17
